【摘要】：正食管癌是指下咽到食管胃結(jié)合部之間食管上皮來源的癌,男性較多。在我國(guó)食管癌是一種常見的惡性腫瘤,目前占我國(guó)腫瘤死亡率的第4位。我國(guó)的食管癌90%以上為鱗狀細(xì)胞癌,少數(shù)為腺癌。食管癌患者就診時(shí)絕大多數(shù)已屬于中晚期。目前食管癌的主要治療手段仍然是手術(shù)、放射治療和化療。然而無論是手術(shù)還是放化療其臨床療效均遠(yuǎn)不能令人滿意,手術(shù)的5年生存率為15%~39%;而放化療的5年生存率為8%~15%。分子靶向治療是在細(xì)胞分子水平
[Abstract]:Positive esophageal cancer refers to the esophageal epithelial origin from hypopharynx to the junction of esophagus and stomach, which is more in men. Esophageal cancer is a common malignant tumor in China, which accounts for the fourth place of tumor mortality in China. More than 90% of esophageal cancer in China is squamous cell carcinoma and a few are adenocarcinoma. Most of the patients with esophageal cancer were in the middle and late stages. At present, the main treatment of esophageal cancer is still surgery, radiotherapy and chemotherapy. However, the clinical efficacy of both surgery and radiotherapy and chemotherapy was far from satisfactory. The 5-year survival rate was 15% 鈮，

本文編號(hào)：2478964